Management of Pre-Menopause Symptoms
Venlafaxine (75 mg/day) is the first-line pharmacological treatment for managing vasomotor symptoms in pre-menopause, with a 61% reduction in hot flash scores compared to placebo. 1
Pharmacological Options for Vasomotor Symptoms
First-Line Options:
SSRIs/SNRIs:
Anticonvulsants:
Second-Line Options:
Antihypertensives:
Other options:
Management of Genitourinary Symptoms
For Vaginal Dryness and Atrophy:
Non-hormonal options:
- Water-based lubricants and moisturizers (first-line) 2
Hormonal options (if non-hormonal treatments fail):
Non-Pharmacological Interventions
Lifestyle Modifications:
- Weight management: ≥10% weight loss significantly reduces hot flash symptoms 1
- Smoking cessation: Improves both frequency and severity of hot flashes 1
- Exercise: 150 minutes weekly of moderate exercise reduces menopausal symptoms 1
- Alcohol limitation: Helpful if alcohol triggers hot flashes 1
Dietary Approaches:
- Calcium (1000 mg/day) and vitamin D (800-1000 IU/day) supplementation 1
Mind-Body Therapies:
- Acupuncture: Shown to be equivalent to or better than venlafaxine or gabapentin 1
- Cognitive behavioral therapy (CBT): Reduces perceived burden of hot flashes 1
- Paced respiration and relaxation techniques: Significant benefit in symptom reduction 1
- Yoga: Improves quality of life associated with menopause 1
Practical Management:
- Dressing in layers
- Using cold packs
- Identifying personal triggers 1
Treatment Algorithm
Initial Assessment:
- Determine symptom severity
- Screen for contraindications to medications
- Evaluate cardiovascular risk factors 1
For Vasomotor Symptoms:
For Genitourinary Symptoms:
Follow-up:
Important Considerations
- Hormone therapy (estrogen with or without progestin) carries significant risks including increased stroke, DVT, PE, MI, and breast cancer risk 1
- For women with a uterus who use systemic estrogen, progestogen should be added to reduce endometrial cancer risk 4
- Selective serotonin-norepinephrine reuptake inhibitors (SNRIs) and selective serotonin reuptake inhibitors (SSRIs) should be offered to help mitigate vasomotor symptoms 2
Remember that pre-menopausal symptoms can last much longer than previously thought—median duration of 11.8 years for women affected in early perimenopause versus 3.4 years for those whose symptoms start after menopause 5.